Literature DB >> 16734623

Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells.

M von Lilienfeld-Toal1, J Nattermann, G Feldmann, E Sievers, S Frank, J Strehl, I G H Schmidt-Wolf.   

Abstract

gammadelta T cells account for up to 10% of T lymphocytes in the peripheral blood of healthy donors. They can be activated by cytokines such as interleukin (IL)-2, IL-12 and IL-15, express natural killer (NK) cell markers such as NKG2D and show cytotoxic activity against several tumour cells, including multiple myeloma. Here, we present activated polyclonal gammadelta T cells from healthy donors with an NK T cell-like phenotype expressing the natural cytotoxicity receptor NKp44. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 have been regarded as specific NK receptors; only two gammadelta T cell clones described so far expressed NKp 44. Isolated polyclonal gammadelta T cells cultured for 7 days according to the cytokine-induced killer cell (CIK) protocol with additional IL-15 revealed a surface expression of NKp44 of 8+/-7% (n=22). This could be confirmed by detection of NKp 44 mRNA by reverse transcription-polymerase chain reaction (RT-PCR). gammadelta T cells exhibited a marked cytotoxic activity against myeloma cells, which could be reduced by inhibition of NKp44. To our knowledge, this is the first description of the expression of NKp44 on polyclonal gammadelta T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16734623      PMCID: PMC1941970          DOI: 10.1111/j.1365-2249.2006.03078.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  An activating immunoreceptor complex formed by NKG2D and DAP10.

Authors:  J Wu; Y Song; A B Bakker; S Bauer; T Spies; L L Lanier; J H Phillips
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

2.  Differential effects of IL-2 and IL-15 on the death and survival of activated TCR gamma delta+ intestinal intraepithelial lymphocytes.

Authors:  C L Chu; S S Chen; T S Wu; S C Kuo; N S Liao
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

3.  Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

Authors:  M Massaia; P Borrione; S Battaglio; S Mariani; E Beggiato; P Napoli; C Voena; A Bianchi; M Coscia; B Besostri; S Peola; T Stiefel; J Even; D Novero; M Boccadoro; A Pileri
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

4.  Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

Authors:  V L Reichardt; C Y Okada; A Liso; C J Benike; K E Stockerl-Goldstein; E G Engleman; K G Blume; R Levy
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

5.  Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.

Authors:  V Groh; R Rhinehart; H Secrist; S Bauer; K H Grabstein; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

6.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Authors:  S Bauer; V Groh; J Wu; A Steinle; J H Phillips; L L Lanier; T Spies
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

7.  HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Authors:  Ennio Carbone; Paola Neri; Maria Mesuraca; Mariateresa T Fulciniti; Takemi Otsuki; Daniela Pende; Veronika Groh; Thomas Spies; Giuditta Pollio; David Cosman; Lucio Catalano; Pierfrancesco Tassone; Bruno Rotoli; Salvatore Venuta
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

8.  Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

Authors:  M J Robertson; K J Cochran; C Cameron; J M Le; R Tantravahi; J Ritz
Journal:  Exp Hematol       Date:  1996-02       Impact factor: 3.084

9.  NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily.

Authors:  C Cantoni; C Bottino; M Vitale; A Pessino; R Augugliaro; A Malaspina; S Parolini; L Moretta; A Moretta; R Biassoni
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

10.  NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis.

Authors:  M Vitale; C Bottino; S Sivori; L Sanseverino; R Castriconi; E Marcenaro; R Augugliaro; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  27 in total

Review 1.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

2.  Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity.

Authors:  Charles T Spencer; Getahun Abate; Azra Blazevic; Daniel F Hoft
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes.

Authors:  Gabriele Pizzolato; Hannah Kaminski; Marie Tosolini; Don-Marc Franchini; Fréderic Pont; Fréderic Martins; Carine Valle; Delphine Labourdette; Sarah Cadot; Anne Quillet-Mary; Mary Poupot; Camille Laurent; Loic Ysebaert; Serena Meraviglia; Francesco Dieli; Pierre Merville; Pierre Milpied; Julie Déchanet-Merville; Jean-Jacques Fournié
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-22       Impact factor: 11.205

4.  Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Authors:  Selim Kuçi; Eva Rettinger; Bernhard Voss; Gerrit Weber; Miriam Stais; Hermann Kreyenberg; Andre Willasch; Zyrafete Kuçi; Ewa Koscielniak; Stephan Klöss; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

5.  Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.

Authors:  Qu Cui; Hironobu Shibata; Asuka Oda; Hiroe Amou; Ayako Nakano; Kenichiro Yata; Masahiro Hiasa; Keiichiro Watanabe; Shingen Nakamura; Hirokazu Miki; Takeshi Harada; Shiro Fujii; Kumiko Kagawa; Kyoko Takeuchi; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  Int J Hematol       Date:  2011-06-23       Impact factor: 2.490

6.  Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.

Authors:  Atif S M Idrees; Tomoharu Sugie; Chiyomi Inoue; Kaoru Murata-Hirai; Haruki Okamura; Craig T Morita; Nagahiro Minato; Masakazu Toi; Yoshimasa Tanaka
Journal:  Cancer Sci       Date:  2013-03-19       Impact factor: 6.716

7.  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Authors:  Vladimir Jurisic; Tatjana Srdic; Gordana Konjevic; Olivera Markovic; Milica Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 8.  Oncogenic stress sensed by the immune system: role of natural killer cell receptors.

Authors:  David H Raulet; Nadia Guerra
Journal:  Nat Rev Immunol       Date:  2009-08       Impact factor: 53.106

Review 9.  Lymphocyte-mediated Immune Regulation in Health and Disease: The Treg and γδ T Cell Co-conspiracy.

Authors:  Kyle K Payne
Journal:  Immunol Invest       Date:  2016-09-12       Impact factor: 3.657

10.  Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells.

Authors:  Kelly Hudspeth; Bruno Silva-Santos; Domenico Mavilio
Journal:  Front Immunol       Date:  2013-03-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.